Predictors of HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients treated with nucleotide analogs plus polyethylene glycol interferon
IntroductionThe minority of the chronic hepatitis B (CHB) patients received polyethylene glycol interferon (PEG-IFN) combined with nucleotide analogs (NAs) can obtain hepatitis B surface antigen (HBsAg) clearance.MethodsIn order to find out the advantaged population, we retrospectively collected 122...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2024.1510230/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841555097806438400 |
|---|---|
| author | Yan Peng Mingzhe Ma Ting Liu Wenmin He Shutao Lin Wa Zhong Xiaohui Min |
| author_facet | Yan Peng Mingzhe Ma Ting Liu Wenmin He Shutao Lin Wa Zhong Xiaohui Min |
| author_sort | Yan Peng |
| collection | DOAJ |
| description | IntroductionThe minority of the chronic hepatitis B (CHB) patients received polyethylene glycol interferon (PEG-IFN) combined with nucleotide analogs (NAs) can obtain hepatitis B surface antigen (HBsAg) clearance.MethodsIn order to find out the advantaged population, we retrospectively collected 122 CHB patients treated with NAs alone or NAs plus PEG-IFN for 48 weeks, who were admitted to Sun Yat-sen Memorial Hospital from 2019 to 2024.ResultsWe found HBsAg clearance rate in NAs plus PEG-IFN group was 40.98%, which was significantly higher than that in the NAs group. Thus, NAs plus PEG-IFN therapy served as a relatively ideal regimen and the patients received combined treatment were then incorporated for further analysis for searching efficacy predictors. Through using univariate and multivariate analysis, we confirmed the predictive value of HBsAg, alanine aminotransferase (ALT) at week 24, and ALT change values from baseline to week 24. The area under the receiver operating characteristic (ROC) curve of each indicators ranged from 0.663 to 0.982.DiscussionIn conclusion, our study verified the clinical value of NAs plus PEG-IFN for treating CHB patients. Moreover, for the first time, we found ALT change values from baseline to week 24 (dALT2) could act as a novel independent clinical efficacy predictors in the forementioned population. |
| format | Article |
| id | doaj-art-85c00b3ac69b49d3b0add32a08fc91f7 |
| institution | Kabale University |
| issn | 2296-858X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-85c00b3ac69b49d3b0add32a08fc91f72025-01-08T06:12:06ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-01-011110.3389/fmed.2024.15102301510230Predictors of HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients treated with nucleotide analogs plus polyethylene glycol interferonYan Peng0Mingzhe Ma1Ting Liu2Wenmin He3Shutao Lin4Wa Zhong5Xiaohui Min6Department of Gastroenterology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaDepartment of Gastroenterology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaDepartment of Infectious Disease, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaDepartment of Gastroenterology, Shenshan Medical Center, Memorial Hospital of Sun Yat-sen University, Shanwei, ChinaDepartment of Infectious Diseases, Shenshan Medical Center, Memorial Hospital of Sun Yat-sen University, Shanwei, ChinaDepartment of Gastroenterology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaDepartment of Gastroenterology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, ChinaIntroductionThe minority of the chronic hepatitis B (CHB) patients received polyethylene glycol interferon (PEG-IFN) combined with nucleotide analogs (NAs) can obtain hepatitis B surface antigen (HBsAg) clearance.MethodsIn order to find out the advantaged population, we retrospectively collected 122 CHB patients treated with NAs alone or NAs plus PEG-IFN for 48 weeks, who were admitted to Sun Yat-sen Memorial Hospital from 2019 to 2024.ResultsWe found HBsAg clearance rate in NAs plus PEG-IFN group was 40.98%, which was significantly higher than that in the NAs group. Thus, NAs plus PEG-IFN therapy served as a relatively ideal regimen and the patients received combined treatment were then incorporated for further analysis for searching efficacy predictors. Through using univariate and multivariate analysis, we confirmed the predictive value of HBsAg, alanine aminotransferase (ALT) at week 24, and ALT change values from baseline to week 24. The area under the receiver operating characteristic (ROC) curve of each indicators ranged from 0.663 to 0.982.DiscussionIn conclusion, our study verified the clinical value of NAs plus PEG-IFN for treating CHB patients. Moreover, for the first time, we found ALT change values from baseline to week 24 (dALT2) could act as a novel independent clinical efficacy predictors in the forementioned population.https://www.frontiersin.org/articles/10.3389/fmed.2024.1510230/fullnucleoside analogspegylated interferonHBeAg-negativechronic hepatitis BHBsAg clearance |
| spellingShingle | Yan Peng Mingzhe Ma Ting Liu Wenmin He Shutao Lin Wa Zhong Xiaohui Min Predictors of HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients treated with nucleotide analogs plus polyethylene glycol interferon Frontiers in Medicine nucleoside analogs pegylated interferon HBeAg-negative chronic hepatitis B HBsAg clearance |
| title | Predictors of HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients treated with nucleotide analogs plus polyethylene glycol interferon |
| title_full | Predictors of HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients treated with nucleotide analogs plus polyethylene glycol interferon |
| title_fullStr | Predictors of HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients treated with nucleotide analogs plus polyethylene glycol interferon |
| title_full_unstemmed | Predictors of HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients treated with nucleotide analogs plus polyethylene glycol interferon |
| title_short | Predictors of HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients treated with nucleotide analogs plus polyethylene glycol interferon |
| title_sort | predictors of hbsag seroclearance in hbeag negative chronic hepatitis b patients treated with nucleotide analogs plus polyethylene glycol interferon |
| topic | nucleoside analogs pegylated interferon HBeAg-negative chronic hepatitis B HBsAg clearance |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2024.1510230/full |
| work_keys_str_mv | AT yanpeng predictorsofhbsagseroclearanceinhbeagnegativechronichepatitisbpatientstreatedwithnucleotideanalogspluspolyethyleneglycolinterferon AT mingzhema predictorsofhbsagseroclearanceinhbeagnegativechronichepatitisbpatientstreatedwithnucleotideanalogspluspolyethyleneglycolinterferon AT tingliu predictorsofhbsagseroclearanceinhbeagnegativechronichepatitisbpatientstreatedwithnucleotideanalogspluspolyethyleneglycolinterferon AT wenminhe predictorsofhbsagseroclearanceinhbeagnegativechronichepatitisbpatientstreatedwithnucleotideanalogspluspolyethyleneglycolinterferon AT shutaolin predictorsofhbsagseroclearanceinhbeagnegativechronichepatitisbpatientstreatedwithnucleotideanalogspluspolyethyleneglycolinterferon AT wazhong predictorsofhbsagseroclearanceinhbeagnegativechronichepatitisbpatientstreatedwithnucleotideanalogspluspolyethyleneglycolinterferon AT xiaohuimin predictorsofhbsagseroclearanceinhbeagnegativechronichepatitisbpatientstreatedwithnucleotideanalogspluspolyethyleneglycolinterferon |